Symposium 13: Reach and meaning of the sarcopenia in T2D

Authors

  • Claudio Daniel González Department of Pharmacology, CEMIC University Institute. University of Buenos Aires (UBA), Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v54i3Sup.323

Keywords:

sarcopenia, diabetes

Abstract

Symposium 13: Sarcopenia and diabetes

Reach and meaning of the sarcopenia in T2D

Clinically defined, we understand sarcopenia as the progressive and generalized loss of mass and skeletal muscle strength, which leads to a decrease in physical performance. Three stages of evolution tend to be distinguished as: 1- Presarcopenia. Muscle mass reduced without an impact on strength or performance; 2- Sarcopenia. Muscle mass reduced with a reduction of strength or performance; 3- Severe sarcopenia. The three criteria are present. Sarcopenia is more frequent in patients with obesity and also in patients with diabetes.

It has been estimated that the presence of diabetes increases the risk of sarcopenia a 50% when it is adapted to age, sex and other variables. Sarcopenia seems to be associated with a mortality excess and it increases the risk of fallings or fractures, especially in patients with diabetes (in interaction with the increase of bone fragility and other factors such as neuropathy, visual alterations, obesity, arrhythmia, and hypoglycemia).

Author Biography

Claudio Daniel González, Department of Pharmacology, CEMIC University Institute. University of Buenos Aires (UBA), Autonomous City of Buenos Aires, Argentina

Pharmacologist doctor; Advisor on the methodology of the clinical and epidemiological evidence qualification processes

Published

2023-01-10

How to Cite

González, C. D. (2023). Symposium 13: Reach and meaning of the sarcopenia in T2D. Journal of the Argentine Society of Diabetes, 54(3Sup), 49–49. https://doi.org/10.47196/diab.v54i3Sup.323

Most read articles by the same author(s)

1 2 3 > >>